Vivani Medical to Showcase Miniature Drug Implants at Investor Conferences

ALAMEDA, Calif., Sept. 03, 2026 /CourierPR/ -- Vivani Medical, Inc., a clinical-stage biopharmaceutical company known for its innovative NanoPortal™ technology, will be showcasing its miniature, ultra-long-acting drug implants at two upcoming investor conferences in New York City.

On September 10, 2026, the company will participate in the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference at the Metropolitan Club in New York. Vivani will also present at the H.C. Wainwright 28th Annual Global Investment Conference, which will take place at the Lotte New York Palace Hotel from September 14 to 16, 2026.

A pre-recorded company presentation for the H.C. Wainwright conference will be accessible starting September 11, 2026, at 7 a.m. Eastern Time. Interested parties can view it via this link: <https://journey.ct.events/view/cd7ac7c4-e1df-4951-ab94-1fb0727c8270>.

Vivani Medical, Inc., leverages its proprietary NanoPortal™ platform to develop biopharmaceutical implants that deliver drug molecules over extended periods, ensuring patient adherence and improving tolerance to medication. The company’s portfolio includes GLP-1 based implants for treating metabolic diseases such as obesity and type 2 diabetes. These implants are designed for administration once or twice a year, offering patients the opportunity to benefit fully from their medication without the challenges of daily or weekly oral or injectable dosing.

Medication non-adherence, a significant issue affecting approximately 50% of patients, including those on daily pills, poses a major health concern. Vivani’s technology addresses this by providing a solution that reduces the frequency of dosing and enhances the reliability of treatment, thereby improving patient outcomes.

Forward-looking statements within this press release include the company’s plans and expectations for its technology, products, and business strategies. Vivani cautions that these statements are subject to various risks and uncertainties that could cause actual results to differ from those predicted. The company encourages readers to review its filings with the U.S. Securities and Exchange Commission for additional information on risks and uncertainties that could impact its business.